TechsoMed

Executive Summary

TechsoMed is an Israeli med‑tech company commercializing BioTraceIO360, an AI‑driven, hardware‑agnostic software platform for image‑guided minimally invasive cancer ablation. The platform uniquely compresses thousands of imaging frames into a 3‑D, risk‑aware interface, providing real‑time margin visualization, needle‑path guidance, and the first FDA‑cleared tissue‑response prediction for liver and kidney ablation. By addressing the critical need for procedural precision and outcome predictability, TechsoMed aims to reduce recurrence rates and improve patient outcomes in interventional oncology. Founded in 2015 and having raised $10M, the company is now in its commercial phase, targeting the growing global ablation market valued at over $2B. TechsoMed’s competitive edge lies in its AI‑native, platform‑agnostic approach that integrates seamlessly with existing imaging and ablation systems, lowering adoption barriers for hospitals. With its FDA clearance serving as a key validation, the company is well‑positioned to capture share in the rapidly expanding interventional oncology space. Upcoming catalysts include potential expansion of its FDA clearance to additional organs (e.g., lung), strategic partnerships with ablation device manufacturers to bundle software with hardware, and a Series B fundraise to scale sales and marketing efforts. If successful, TechsoMed could become a standard‑of‑care software layer for image‑guided cancer therapy, driving significant adoption and revenue growth.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for lung ablation indication60% success
• Q4 2026Strategic partnership with a major ablation device manufacturer50% success
• Q2 2026Series B funding round to accelerate commercialization70% success